![\"\"](\"https:\/\/www.newsbeep.com\/us\/wp-content\/uploads\/2025\/08\/image-2025-08-19T144900.735.png\")
<\/p>\n\t\t\t\t\t\t<\/p>\n
Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI<\/a>, a next-generation biotechnology company and one of the world\u2019s first fully vertically-integrated molecular testing platforms. Specializing in polymerase chain reaction (PCR)-based infectious disease detection, OSPRI develops and delivers advanced tools that improve access to high-quality care across key healthcare segments, including women\u2019s health, primary care, urgent care, urology, hospitals, and clinical reference laboratories.<\/p>\n In addition to assay development, OSPRI delivers an end-to-end solution\u2014covering manufacturing, lab buildout, revenue cycle management, and regulatory support\u2014empowering providers to operate high-complexity labs in-house with greater speed, accuracy, and financial control.<\/p>\n \u201cPCR testing is foundational for infectious disease detection, but cost and complexity have kept it out of reach for many,\u201d said Steve M. Sorey, Partner at OSPRI. \u201cTo unlock widespread adoption, we must reduce both. At OSPRI, we\u2019re obsessed with doing more with less\u2014making PCR faster, cheaper, and better for everyone involved.\u201d<\/p>\n The merger is financed by up to $30 million of strategic funding from Catalio Capital Management, a leading healthcare investment firm with deep expertise in diagnostics. This partnership will support OSPRI\u2019s continued growth, platform development, and national expansion.<\/p>\n \u201cOSPRI delivers a powerful solution for physician groups and laboratories\u2014simplifying infectious disease testing while creating strong clinical and commercial value,\u201d said Jonathan Blankfein, Partner at Catalio. \u201cWe\u2019re proud to support their mission to expand access to rapid, provider-centric diagnostics.\u201d<\/p>\n OSPRI\u2019s scientific leadership includes Dr. Rahul Sharma (Chief Science Officer), Dr. Sadia Almas (Chief Innovation Officer), and Dr. Alaina Vincent (Chief Clinical Officer). The company\u2019s technology is redefining PCR testing through:<\/p>\n 20\u201350% reduction in overall testing costs Built on a legacy of innovation, OSPRI unites the complementary strengths of its founding entities. With roots dating back to 2015, Community Direct DX has launched over 60 labs nationwide. Scienetix brings deep expertise in molecular bioengineering, while Advanta R&D has led advancements in high-resolution genomics and contributed to national public health initiatives.<\/p>\n \u201cOur production capabilities have grown exponentially,\u201d said Jeremy Adamic, Partner at OSPRI. \u201cFrom a limited menu and basic QC, we now deliver over 40,000 tests per day with multilayered quality control\u2014scaling both volume and reliability.\u201d<\/p>\n Over the next 12\u201324 months, OSPRI plans to expand its R&D team by 40% and grow commercial operations by 25% to meet increasing demand. Headquartered in McKinney, Texas, the company currently serves clients across 20 states and multiple clinical specialties.<\/p>\n \u201cOSPRI exists to solve the real problems of cost and complexity in infectious disease testing,\u201d said Dr. Alaina Vincent. \u201cInnovation should be accessible\u2014not exclusive. Our goal is to enable better, faster care for more patients by equipping providers with the tools they need to lead.\u201d<\/p>\n ABOUT OSPRI ABOUT CATALIO CAPITAL MANAGEMENT <\/p>\n Catalio Capital Management, LP, is a New York-based investment firm focused on the full lifecycle of innovative healthcare investing across private, public and credit markets. Catalio has exclusive partnerships with world-renowned serial scientist-entrepreneurs from around the globe who each have extensive academic and scientific achievements and who have also started multiple well-established companies based on their research. Catalio has offices in New York, London, and Washington, D.C. Learn more about Catalio Capital Management by visiting www.cataliocapital.com<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"Community Direct DX (CDx), Scienetix, and the R&D division of Advanta Genetics have merged to form OSPRI, a…\n","protected":false},"author":2,"featured_media":95320,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[50],"tags":[200,79],"class_list":["post-95319","post","type-post","status-publish","format-standard","has-post-thumbnail","category-genetics","tag-genetics","tag-science"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/95319","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/comments?post=95319"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/posts\/95319\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media\/95320"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/media?parent=95319"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/categories?post=95319"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/us\/wp-json\/wp\/v2\/tags?post=95319"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\n50\u201370% decrease in testing time and workflow steps
\nUp to 4x increase in testing capacity
\nCustomized assays tailored to provider specialty and patient population
\nReduced lab errors through simplified workflows
\nA comprehensive menu of 80+ PCR tests covering 250+ pathogens and AMR genes<\/p>\n
OSPRI is a biotechnology company revolutionizing infectious disease testing through a fully integrated platform. With a focus on PCR technology, OSPRI enables healthcare providers and laboratories to manage high-complexity infectious disease testing in-house\u2014cutting costs, accelerating results, and improving clinical outcomes. Learn more at www.OspriBio.com<\/a>.<\/p>\n